Files and links (1)
Accepted (AM)Open Access (License Unspecified), Open
Journal article
The current status and future directions of hepatitis B antiviral drug discovery
Expert opinion on drug discovery, v 12(1)
02 Jan 2017
PMID: 27797587
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Introduction: The current standard care of chronic hepatitis B fails to induce a durable off-drug control of hepatitis B virus (HBV) replication in the majority of treated patients. The primary reasons are its inability to eliminate the covalently closed circular (ccc) DNA, the nuclear form of HBV genome, and restoration of the dysfunctional host antiviral immune response against the virus. Accordingly, discovery and development of therapeutics to completely stop HBV replication, eliminate or functionally inactivate cccDNA as well as activate a functional antiviral immune response against HBV are the primary efforts for finding a cure for chronic hepatitis B.
Area covered: Herein, the authors highlight the current efforts of HBV drug discovery and offer their opinions for the future directions of this research.
Expert opinion: The authors believe that through a consecutive or overlapping three-stage antiviral and immunotherapy program to: (i) completely stop HBV replication and cccDNA amplification; (ii) reduce viral antigen load and induce HBV surface antigen (HBsAg) seroclearance through eradication or inactivation of cccDNA and RNA interference-mediated degradation of viral mRNA and (iii) activate a functional antiviral immune response against HBV through therapeutic immunization or immunotherapy, a functional cure of chronic HBV infection can be achieved in the majority of chronic HBV carriers.
Metrics
Details
- Title
- The current status and future directions of hepatitis B antiviral drug discovery
- Creators
- Liudi Tang - Drexel UniversityQiong Zhao - Baruch S. Blumberg InstituteShuo Wu - Baruch S. Blumberg InstituteJunjun Cheng - Baruch S. Blumberg InstituteJinhong Chang - Baruch S. Blumberg InstituteJu-Tao Guo - Baruch S. Blumberg Institute
- Publication Details
- Expert opinion on drug discovery, v 12(1)
- Publisher
- Taylor & Francis
- Grant note
- R01AI113267 / National Institute of Allergy and Infectious Diseases (10.13039/100000060)
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Microbiology and Immunology
- Web of Science ID
- WOS:000390240200002
- Scopus ID
- 2-s2.0-85002761696
- Other Identifier
- 991019168471404721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Pharmacology & Pharmacy